Zymeworks Inc.

NasdaqGS:ZYME 株式レポート

時価総額：US$914.7m

Zymeworks マネジメント

マネジメント 基準チェック /24

Zymeworksの CEO はKen Galbraithで、 Jan2022年に任命され、 の在任期間は 2.83年です。 の年間総報酬は$ 3.37Mで、 18.5%給与と81.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.034%を直接所有しており、その価値は$ 314.29K 。経営陣と取締役会の平均在任期間はそれぞれ1.8年と1.6年です。

主要情報

Ken Galbraith

最高経営責任者

US$3.4m

報酬総額

CEO給与比率18.5%
CEO在任期間2.8yrs
CEOの所有権0.03%
経営陣の平均在職期間1.8yrs
取締役会の平均在任期間1.6yrs

経営陣の近況

Recent updates

Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab

Nov 04

Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Nov 03
Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook

Nov 01
Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook

Zymeworks Approaching A Moment Of Truth With Zanidatamab

Sep 27

Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week

Aug 07
Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week

Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up

Jul 26
Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up

Zymeworks: A Somewhat Complicated Story

Jul 09

Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

Jun 12
Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

May 03
Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data

Apr 18

Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments

Mar 05

Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion

Feb 06

Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind

Jan 31

Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M

Nov 08

Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone

Oct 26

Zymeworks: A Roller Coaster Year

Jul 26

Zymeworks And The Blue Falcon Elucidation

May 17

CEO報酬分析

Zymeworks の収益と比較して、Ken Galbraith の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$114m

Jun 30 2024n/an/a

-US$113m

Mar 31 2024n/an/a

-US$126m

Dec 31 2023US$3mUS$625k

-US$119m

Sep 30 2023n/an/a

US$205m

Jun 30 2023n/an/a

US$186m

Mar 31 2023n/an/a

US$173m

Dec 31 2022US$7mUS$582k

US$124m

Sep 30 2022n/an/a

-US$224m

Jun 30 2022n/an/a

-US$237m

Mar 31 2022n/an/a

-US$240m

Dec 31 2021n/an/a

-US$212m

Sep 30 2021n/an/a

-US$211m

Jun 30 2021n/an/a

-US$223m

Mar 31 2021n/an/a

-US$194m

Dec 31 2020n/an/a

-US$181m

Sep 30 2020n/an/a

-US$215m

Jun 30 2020n/an/a

-US$173m

Mar 31 2020n/an/a

-US$163m

Dec 31 2019US$167kn/a

-US$145m

報酬と市場: Kenの 総報酬 ($USD 3.37M ) は、 US市場 ($USD 3.24M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Kenの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Ken Galbraith (61 yo)

2.8yrs

在職期間

US$3,374,876

報酬

Mr. Kenneth H. Galbraith, also known as Ken, C. A., is Director of AudienceView Ticketing Corporation. He serves as Chairman of Zomp. He is Director of NeurAxon Inc. He is CEO & Chairman of the Board of Zy...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Kenneth Galbraith
Chairman of the Board2.8yrsUS$3.37m0.034%
$ 314.3k
Paul Moore
Chief Scientific Officer2.3yrsUS$1.68m0.011%
$ 97.4k
Leone Patterson
Executive VP and Chief Business & Financial Officerless than a yearデータなしデータなし
Mark Hollywood
Executive VP and Head of Technical & Manufacturing Operationsno dataデータなしデータなし
Daniel Dex
Senior VPno dataデータなしデータなし
Diana Papove
Senior Manager of Corporate Communicationsno dataデータなしデータなし
Lindsey Foulkes
Vice President of Corporate Developmentno dataデータなしデータなし
Laura O'Connor
Vice President of Human Resources & DEI1.8yrsデータなしデータなし
Jeffrey Smith
Executive VP & Chief Medical Officerno dataデータなしデータなし
John Fann
Senior Vice President of Process Sciencesless than a yearデータなしデータなし
Ryan Dercho
Senior Director of Corporate Affairsno dataデータなしデータなし
Nina Weisser
Director of Multispecific Antibody Therapeuticsno dataデータなしデータなし

1.8yrs

平均在職期間

61yo

平均年齢

経験豊富な経営陣: ZYMEの経営陣は 経験豊富 とはみなされません ( 1.8年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称ポジション在職期間報酬所有権
Kenneth Galbraith
Chairman of the Board2.8yrsUS$3.37m0.034%
$ 314.3k
Hollings Renton
Independent Director7.8yrsUS$264.00k0%
$ 0
Nancy Davidson
Independent Directorless than a yearUS$441.02k0%
$ 0
Neil Gallagher
Independent Directorless than a yearデータなしデータなし
Kelvin Neu
Independent Director4.7yrsUS$262.46k0%
$ 0
Susan Mahony
Lead Independent Director5.4yrsUS$261.83k0%
$ 0
Alessandra Cesano
Independent Directorless than a yearデータなし0%
$ 0
Derek John Miller
Independent Director1.6yrsUS$555.15k0%
$ 0
Troy Cox
Independent Director5.4yrsUS$263.83k0.011%
$ 99.2k
Scott Platshon
Independent Directorless than a yearデータなしデータなし
Carlos Campoy
Independent Director1.4yrsUS$508.97k0%
$ 0
Troy Cox
no dataデータなしデータなし

1.6yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: ZYMEの 取締役会 は 経験豊富 ではない ( 1.6年の平均在任期間) ため、新しい取締役会が必要であると考えられます。